No Data
Junshi Bio (688180.SH) signed a licensing agreement involving two dual-target fusion proteins for the treatment of malignant tumors.
Junshi bio (688180.SH) announced that recently, the company signed a "License Agreement" with the licensor; the licensor granted...
Shanghai Junshi Biosciences' Unit Gets Marketing Approval for Cancer Drug by UK Regulator
Junshi Bio (688180.SH): Toripalimab has been approved for marketing by the United Kingdom Medicines and Healthcare products Regulatory Agency.
Gelonghui, November 17th丨Junshi Bio (688180.SH) announced that its wholly-owned subsidiary TopAlliance Biosciences Inc. has received approval from the United Kingdom's Medicines and Healthcare products Regulatory Agency (hereinafter referred to as "MHRA") for the marketing authorization of the product Tretinoin monoclonal antibody (UK commodity name: LOQTORZI). This approval is for the treatment of two indications: Tretinoin monoclonal antibody in combination with cisplatin and gemcitabine for first-line treatment of adult patients with recurrent, unresectable or radiotherapy-resistant, or metastatic nasopharyngeal carcinoma, and Tretinoin monoclonal antibody in combination with cisplatin and paclitaxel for not...
Express News | Junshi Biosciences Announces UK Mhra Approval for Marketing of Toripalimab
Junshi Bio (01877.HK): Toripalimab has been approved for listing by the United Kingdom's pharmaceutical and healthcare products regulatory agency.
Gelonghui, November 15th丨Junshi Bio (01877.HK) announced that its wholly-owned subsidiary Top Alliance Biosciences Inc. has received marketing authorization from the United Kingdom's Medicines and Healthcare products Regulatory Agency ("MHRA") for the product Trelagliptin (UK brand name: LOQTORZI), approved for the treatment of two indications: Trelagliptin in combination with cisplatin and gemcitabine for first-line treatment of adult patients with recurrent, inoperable or radiotherapy-resistant, or metastatic nasopharyngeal carcinoma, and Trelagliptin in combination with cisplatin and paclitaxel for unresectable advanced.
Express News | Shanghai Junshi Biosciences - Approval by Mhra for Marketing of Toripalimab
Further Weakness as Shanghai Junshi Biosciences (HKG:1877) Drops 3.2% This Week, Taking Three-year Losses to 83%No Data
No Data
